Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

SALT LAKE CITY - Myriad Genetics Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine, has announced a strategic partnership with jscreen™, an ...

SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health ...

SALT LAKE CITY - Myriad Genetics Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine, has announced a strategic partnership with jscreen™, an organization ...

Myriad develops and offers genetic tests that help assess the risk of developing ... improve patient care and lower healthcare costs. For more information, visit . Safe Harbor Statement This ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...